Financial Performance Highlights

Q1 FY27 Key Metrics:

  • Network gross revenue: ₹2,982 crore (16% YoY growth from ₹2,574 crore in Q1 FY26; 12% QoQ growth from ₹2,664 crore)
  • Network operating EBITDA: ₹704 crore (15% YoY growth; 3% QoQ growth)
  • Operating EBITDA margin: 24.8% (vs 24.9% in Q1 FY26 and 26.8% in previous quarter)
  • Profit After Tax (PAT): ₹357 crore (vs ₹345 crore in Q1 FY26 and ₹387 crore in previous quarter)
  • Average occupancy: >75% despite 13% YoY increase in operational bed capacity
  • Occupied Bed Days (OBDs): Up 10% YoY and 5% QoQ
  • Average Length of Stay (ALOS): Reduced by 4% over trailing quarter
  • Average Revenue Per Occupied Bed (ARPOB): ₹81,900 (5% growth both YoY and QoQ)
  • Annualized EBITDA per bed: ₹71 lakh (vs ₹68 lakh in Q1 FY26 and ₹73 lakh in previous quarter)
  • International patient revenue: ₹247 crore (18% YoY growth, 9% of hospital revenues)
  • Digital revenue: ₹941 crore (32% of overall revenue)
  • Website traffic: 97 lakh sessions (41% YoY growth)

Oncology Segment Impact:

  • Share of oncology for in-patient revenues dropped to 22% from 26% in Q1 FY26 due to discontinuation of select high-value chemotherapy drugs for institutional patients
  • Excluding oncology, gross revenue grew 20% and ARPOB grew 9% YoY
  • Oncology expected to normalize from Q3 FY27 onwards

Cash Flow and Debt Position:

  • Network generated free cash flows of ₹397 crore during the quarter
  • ₹386 crore deployed towards acquisition of Kalinga Hospital and Yerawada Properties Private Limited
  • ₹337 crore invested in ongoing capacity expansion projects
  • Net debt: ₹2,384 crore (vs ₹1,908 crore at March 2026 end)
  • Net debt-to-EBITDA ratio remained below 1
  • Increase includes ₹153 crore towards Kalinga acquisition and put option liability for balance stake in Yerawada (Pune project)

Strategic Business Units Performance:

  • Max@Home: Revenue ₹78 crore (32% YoY growth), 16 specialized service lines across 15 cities, 56% repeat transactions
  • Max Lab: Revenue ₹58 crore (20% YoY growth), services in over 60 cities, served over 6 lakh patients during quarter

Capacity Expansion Projects Status

Recently Commissioned/Current Quarter:

  • Max Smart: 50% of 400-bed brownfield tower operationalized (currently at 80% occupancy), remaining 50% beds expected this quarter
  • Nanavati Max: Remaining 50 beds to be operationalized this quarter

Near-term Projects (Next 2-3 years):

1. Max Lucknow: Additional 100 beds in existing 468-bed facility - commissioning over next two quarters

2. Sector 56 Gurgaon: 500 beds - phased commissioning expected by end of CY2026

3. Bhubaneswar: 250 beds - renovation completion within 12 months

4. Nagpur: 100 beds - commissioning expected by FY28

5. Zirakpur, Mohali: 400 beds - commissioning expected in FY28

6. Max Dwarka: Onco day care block (Phase 2) - project complete, awaiting occupancy certificate

7. Dwarka: 260 beds (next phase) - commissioning by FY30

8. Pitampura: 200 beds - commissioning expected in FY29

9. Patparganj: 400 beds - D-wall work started, commissioning by end FY29

10. Nanavati (Phase 2): 271 beds - project work started, commissioning in FY30

11. Pune: 450 beds - IOD received, commissioning expected by FY30

Newly Approved Project:

  • Max Vaishali: Board approved capital expenditure of ₹425 crore for new brownfield tower adding 202 beds to existing 387-bed capacity
  • Building plans approved, construction commenced
  • Project expected to be commissioned before FY30

Acquisition Updates

Max Bhubaneswar (formerly Kalinga Hospital):

  • Contributed ₹19 crore revenue and ₹2 crore EBITDA during post-acquisition period in Q1 FY27
  • Occupancy: 50%
  • ARPOB: ₹35,000
  • Prior to acquisition: Generated revenues of ₹154 crore in FY26
  • Focus on integrating operations, renovating infrastructure, upgrading technology, and enhancing clinical programs
  • Target: Turn around hospital over next 12 months
  • Expected headroom: 50-80% enhancement in both occupancy and ARPOB
  • Minority shareholder litigation: 39% minority shareholders (based outside India) seeking share purchase; company indicates shares are not transactable due to liquidation proceedings against shareholders

Pune Greenfield:

  • Acquired SPV (Yerawada Properties Private Limited), now a subsidiary of the company

New Business Initiatives

Medical Education Business:

  • Received in-principle board approval to enter medical education business
  • Driven by recent National Medical Commission guideline changes allowing for-profit companies to open medical colleges
  • Estimated capital requirement: ₹300 crore for 150-seat medical college
  • Target ROCE: >25-30%
  • Initial plans: Start with Lucknow campus (27-acre campus), then expand to other locations with available land
  • Will include postgraduate courses
  • To be funded through internal accruals
  • Timeline: Commercial operations expected over next few years

Research and Academic Ecosystem:

  • Established standalone Max Research Centre
  • Conducted over 750 clinical trials
  • Completed over 2,200 investigator-initiated studies
  • Published nearly 3,500 papers in index journals
  • Secured over 30 competitively funded research projects
  • Recent grants/awards from: ICMR Centre for Advanced Research in Precision Diabetes, ANRF MAHA MedTech Mission, DBT European Union Dengue Program, India AI Mission initiatives with National Cancer Grid
  • Max Institute of Medical Education (MIME): Trains over 12,000 healthcare professionals annually across 180 programs
  • Postgraduate ecosystem: Over 600 DNB students across clinical specialties

Regulatory and Market Environment

Insurance Empanelment:

  • Ongoing negotiations with GIPSA and other insurance companies
  • Renewals due in September-October 2026
  • 6% automatic price revision agreed in previous negotiations
  • Engagement with IRDAI and insurers for automatic increase linked to inflation level

CGHS Reimbursements:

  • On track for ₹140 crore for FY27
  • Super specialty rates started flowing from June 2026 onwards
  • New portal implementation caused temporary bill processing delays

Parliamentary Standing Committee Recommendations:

  • Management views recommendations as focusing on affordability but believes need for new hospital beds and viability must be balanced
  • No direct reach out to hospitals from the committee
  • Believes policy will eventually be rational and conducive to investments

Corporate Social Responsibility

  • Provided free treatment to over 56,000 patients from economically weaker sections worth ₹78 crore at hospital tariff
  • Spent approximately ₹6 crore on CSR initiatives including medical scholarships, maternal and newborn health, vocational skill training, environmental projects (pond rejuvenation, tree plantations)

Operational Metrics

  • Accounts Receivable: DSO increased from 87 days to 95 days, resulting in ₹250 crore AR build-up in Q1 vs Q4 FY26
  • Effective Tax Rate: Increased compared to previous quarter
  • Direct Costs: Grew 16% YoY (vs 15% revenue growth), primarily due to clinician costs
  • No significant impact from crude price increases on consumable prices

Management Outlook

  • Expect continued growth trajectory with capacity expansion
  • Focus on improving profitability of newly commissioned beds over next 2-3 quarters
  • Medical education business seen as significant future growth driver
  • Willing to consider meaningful acquisitions to accelerate medical education entry
  • Net debt-to-EBITDA could go up to 2.5x for acquisitions
  • ARPOB growth expected to remain superior to inflation due to novel treatments and technology adoption